step 1 semaglutide 2.4 mg weight loss percent 2·4 once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Chronic Weight Management Trial Results

The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria

It belongs to a class of drugs called incretin mimetics, which work by mimicking the effects of naturally occurring hormones in the body that regulate blood sugar levels and appetite

While most people associate nerve damage with diabetes, obesity itself is increasingly recognized as an independent risk factor for peripheral neuropathy

Anderson, MD, MAS, an assistant professor of medicine at the University of Pittsburgh, and Deborah Grady, MD, MPH, a professor emeritus of medicine and of epidemiology and biostatistics at the University of California, San Francisco, reiterated that the findings are reassuring and support preliminary data from the FDA and European Medicines Agency, but the results do not answer definitely whether or not this drug class poses safety concerns regarding mental health

The blood glucose reduction level was calculated by dividing the blood glucose concentration by the concentration before insulin treatment